THE EFFICACY OF SYSTEMIC ENZYME THERAPY IN THE COMPLEX TREATMENT OF TROPHIC ULCERS OF VENOUS ETIOLOGY

Vasilev IM1,2, Bogdanec LI2, Shcherbin SV3

1. Research and Education Center for Medical Science and Technology, Bauman Moscow State Technical University, Moscow, Russia
2. Department of Thoracic Surgery No. 1, Faculty of General Medicine, Pirogov Russian National Research Medical University, Moscow, Russia
3. Department of Morphology, Faculty of Medicine and Biology, Pirogov Russian National Research Medical University, Moscow, Russia

The current strategy for the treatment of venous trophic ulcers (VTU) suggests differentiated approach and a combination of conservative and surgical methods. This paper presents the results of the study of efficacy of systemic enzyme therapy (Phlogenzym by Mucos Pharma, Germany) in patients with varicose veins of lower extremities (CEAP class C6) and stage I, II and III VTU. The study included 38 patients aged 12 to 82 years. The patients were divided into the experimental (n = 20) and the control (n = 18) groups. The treatment lasted 1 month. Silicofix Professional wound dressings (Pharmaplast, Egypt) were used. All patients received Detralex (Les Laboratoires Servier, France) and wore class 2 and 3 knee-high compression socks. Patients of the experimental group also received Phlogenzym for 30 days (3 tablets 3 times a day). Total ulcer epithelization was observed in 8 (40 %) patients by week 3, and in 18 (90 %) patients by the end of treatment compared to 4 (22 %) and 9 (50 %) patients in the control group, respectively. In the control group, the regenerative process in the area of the ulcerous defect was less prominent compared to the experimental group. Immunoassays revealed a significant reduction in CD4+CD25high cells and increased levels of CD4+CD45RO+ T-lymphocytes in the experimental group, corresponding with the observed positive clinical response. The use of immunomodulatory drug Phlogenzym contributed to a more rapid regression of clinical symptoms of chronic venous insufficiency and faster healing of stage I–III venous trophic ulcers.

Keywords: varicose veins of lower extremities, venous trophic ulcer, adaptive immunity, lymphocyte subpopulation

ЭФФЕКТИВНОСТЬ СИСТЕМНОЙ ЭНЗИМОТЕРАПИИ В КОМПЛЕКСНОМ ЛЕЧЕНИИ ТРОФИЧЕСКИХ ЯЗВ ВЕНОЗНОГО ГЕНЕЗА

И. М. Васильев1,2, Л. И. Богданец1, С. В. Щербин3

1. Московский государственный технический университет имени Н. Э. Баумана, Москва
2. Кафедра факультетской хирургии № 1, лечебный факультет, Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва
3. Кафедра морфологии, медико-биологического факультета, Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва

Современная стратегия и тактика лечения венозных трофических язв (ВТЯ) предполагают дифференцированный подход и комбинацию консервативных и хирургических методов. В работе представлены результаты исследования эффективности системной энзимотерапии (препарат «Флогэнзим», Mucos Pharma, Германия) у пациентов с варикозным расширением вен нижних конечностей клинического класса С6 с ВТЯ в I–III стадии раневого процесса. В исследовании участвовали 38 пациентов в возрасте от 12 до 82 лет. Они были разделены на основную (n = 20) и контрольную (n = 18) группы. Лечение длилось 1 мес. Использовали раневые повязки линейки Silicofix Professional (Pharmaplast, France) и носили гольфы 2–3 степени компрессии. В основной группе в протокол лечения включали «Флогэнзим»: курс 30 дней, по 3 таблетки 3 раза в день. В результате полная эпителизация язвы на 3 неделе лечения была отмечена у 8 (40 %) пациентов, к концу лечения — у 18 (90 %), тогда как в контрольной группе — у 4 (22 %) и 9 (50 %) соответственно. У пациентов контрольной группы регенеративные процессы в области язвенного дефекта были слабо выражены по сравнению с основной группой. Иммунологический анализ показал существенное снижение содержания CD4+CD25high-клеток и повышение содержания Т-лимфоцитов с фенотипом CD4+CD45RO+ в основной группе, что соответствовало наблюдаемым положительным изменениям в клинической картине. Включение в протокол лечения иммуномодулирующего препарата «Флогэнзим» способствовало более быстрому регрессу клинических симптомов хронической венозной недостаточности и ускорению регенерации ВТЯ в I–III стадии раневого процесса.

Ключевые слова: варикозное расширение вен нижних конечностей, венозная трофическая язва, адаптивный иммунитет, субпопуляция лимфоцитов

Для корреспонденции: Васильев Иван Михайлович
Ленинск пр-т, д. 10, кorp. 5, г. Москва, 117049; mdivas@mail.ru
Статья поступила: 24.10.2016 Статья принята в печать: 28.10.2016
Varicose veins of lower extremities (VV) are one of the most common pathologic conditions of the peripheral vessels of lower extremities leading to the development of venous trophic ulcers (VTU) in some cases [1, 2]. VTU of lower extremities are a serious problem in modern medicine; in 10% of cases VTU are persistent and non-responsive to conservative therapy [3]. Relapse rates remain high and range from 4.8 to 31.6% after surgery and from 15.0 to 100.0% after complex conservative treatment [4]. It is clear that attempts to influence individual components involved in the pathogenesis of the disease are not effective.

Recent studies show that in the treatment of venous ulcers, elimination of venous hypertension and valvular incompetence seen as the main causes of chronic venous insufficiency (CVI) [5–7] does not provide a desired effect. It is necessary to treat microcirculatory disorders that lead to chronic inflammation in the ulcer, constant leukocyte infiltration and changes in the metabolism of endothelial cells [8]. A characteristic feature of chronic inflammation is an imbalance between the humoral and cell-mediated immunity; however, only limited data are currently available on the role of immune disorders in the pathogenesis of VV [9, 10]. The few and rather contradictory results of the studies of the immune status of patients with VTU indicate that the severity of trophic disorders depends not only on the anatomical characteristics of the vein, but also on the inadequate response of immune cells, which is a chronic damaging factor [11–14].

One of the understudied methods of VTU treatment is systemic enzyme therapy (SET). Several studies have shown its efficacy, in particular when using Wobenzym (Mucos Pharma, Germany) for the treatment of CVI of various etiology (post-thrombotic syndrome disease and varicose vein disease) [15, 16]. The aim of this study was to evaluate the efficacy of conservative therapy supported with systemic enzymes (Phlologenzym by Mucos Pharma).

METHODS

The study included 38 patients with VV (C6) who received treatment for 1 month. The inclusion criteria were stage I–III recurrent VTU with the area of the ulcerous defect up to 30 cm², and patients’ age from 18 to 82 years. The exclusion criteria were the presence of a concomitant pathology: type 1 diabetes, atherosclerosis of lower extremities, systemic vasculitis, rheumatoid arthritis, hormone and immune therapy. The patients were divided into two groups. The control group received conservative treatment: wound dressings, compression and phlebotropic drug therapy. It included 18 patients (mean age of 60.1 ± 10.5 years) and consisted of 12 (66.7%) women and 6 (33.3%) men; 10 (55.6%) patients were >60 years of age. The experimental group received conservative treatment and systemic enzyme therapy with Phlologenzym for 30 days, 3 tablets 3 times a day. It included 20 patients (mean age of 61.2±12.6 years) and consisted of 13 (65.0%) women and 7 (35.0%) men; 13 (65.0%) patients were >60 years of age. Each group included 4 patients with stage III VTU and 3 patients with stage I VTU; the rest of the patients had stage II VTU.

In the course of treatment, wound dressings Silcofix Professional (Pharma plast, Egypt) were used. In patients with stage I VTU, absorbent dressings (Fibroset, Fibroclean Ag) were used. Atraumatic povidone-iodine dressings (Silkofix POVI) were applied on the defect with persistent fibrin deposits after exudation has decreased. In patients with stage II–III VTU, hydrocolloid dressings with silver ions (Fibrocol Ag) were used. At the first sign of epithelialization, hypoadesive mesh coatings with a lipocolloid complex (Fibrotul, Fibrotul Ag) were used. All patients received Detralex (Les Laboratoires Servier, France) for 1 month and wore knee-high compression stockings (classes 2 and 3).

Fasting venous blood samples were taken for immunological analysis in the morning using Vacuette blood collection systems (Greiner Bio One, Germany). Lymphocyte surface receptors were evaluated by multiparameter immunofluorescent staining with monoclonal antibodies (IQ Products, the Netherlands). Before and after treatment, absolute and relative counts of lymphocytes in the peripheral blood with the following surface antigens were determined using laser flow cytometry (FACS Calibur platform, Becton Dickinson, USA) and CellQuest software (BD Biosciences, USA): CD19+, CD3+, CD3-CD4+, CD3-CD8+, CD3-CD25+, CD4-CD25bright, CD4-CD45RA+, CD4-CD45RO+. CD45RA, CD45RO.

For the quantitative assessment of CVI symptoms (“heavy legs”, pain, swelling, cramps) and the analysis of the wound healing dynamics (healing of the ulcer and the condition of the surrounding tissues), we used the Venous Clinical Severity Score (VCSS) and the ulcer and skin condition score. VCSS was used before and after treatment; ulcer assessment was performed before treatment and after 1 month of treatment. To assess the discomfort in daily activities, the Visual Analogue Scale (VAS) was used.

Bacteriological analysis of ulcer discharge was performed at the initial visit and after 2 weeks of treatment. The cultures were assessed using semiautomatic analyzers Sceptor and Crystal (Becton Dickinson). Statistical analysis was performed using Statistica 6.0 software (StatSoft, USA). Statistical significance was determined using Student’s t-test. The differences between mean values and 95% confidence interval were considered statistically significant at p <0.05. The data in the tables are presented as M ± m.

All patients provided written informed consent. The study protocol was approved by the Ethics Committee of Pirogov Russian National Research Medical University in 2013.

RESULTS

Complete healing of ulcers in the control group was observed in 4 (22.2%) patients after 3 weeks of treatment and in 9 (50.0%) patients after 5 weeks. In the experimental group regeneration was much faster; complete epithelialization of the ulcer was observed in 8 (40.0%) patients after 3 weeks of treatment and in 18 (90.0%) patients by the end of treatment (Table 1). Healing was confirmed by the evaluation of such parameters as wound pain, hyperpigmentation, maceration, hyperemia and eczematous dermatitis. In the experimental group, we observed faster ulcer surface clearing of purulent and necrotic tissues, reduction of induration and hyperemia, more active formation of granulation tissue, and basal epithelialization (Table 2). The patients of the experimental group also reported more significant pain relief and reduction of discomfort in the area of the ulcer in the course of treatment compared to the control group (Table 3).

Microbiological tests conducted before treatment identified the presence of Staphylococcus aureus in 40% of patients and its microbial associations in 10% of patients. After 2 weeks of treatment, only non-pathogenic and opportunistic microbes below the critical level of contamination were found in all patients.

In both groups, the analysis of cell subpopulations showed no significant changes in the absolute and relative counts of...
Table 1. The results of treatment with and without Phlogenzym in patients with stage I–III venous trophic ulcers

| Healing | Experimental group (n = 20) | Control group (n = 18) |
|---------|-----------------------------|------------------------|
| Week 1  | 0                           | 0                      |
| Week 2  | 0                           | 0                      |
| Week 3  | 8 (40.0 %)                  | 4 (22.2 %)             |
| Week 4  | 7 (35.0 %)                  | 2 (11.1 %)             |
| Week 5  | 3 (15.0 %)                  | 3 (16.7 %)             |

Note. The results are presented as M ± m. * — p <0.05 when comparing two values within a group.

Table 2. Assessment of ulcers and surrounding tissues before treatment and after 1 week of treatment

| Parameter              | Experimental group (n = 20) | Control group (n = 18) |
|------------------------|-----------------------------|------------------------|
| Wound pain             | 2.4 ± 2.1                   | 1.3 ± 1.2*             |
| Hyperpigmentation      | 1.0                         | 1.0                    |
| Maceration             | 0.4 ± 0.5                   | 0.2 ± 0.3*             |
| Hyperemia              | 0.7 ± 0.5                   | 0.2 ± 0.3*             |
| Eczematous dermatitis  | 0                           | 0                      |

Note. The results are presented as M ± m. * — p <0.05 when comparing two values within a group.

Table 3. Assessment of CVI symptoms severity and the degree of patient’s discomfort before and after treatment

| Parameter                                             | Experimental group (n = 20) | Control group (n = 18) |
|-------------------------------------------------------|-----------------------------|------------------------|
| Severity of clinical manifestations of CVI, the average score (VCSS scale) | 5.6 ± 0.5                   | 2.4 ± 0.7*             |
| The degree of patient’s discomfort, the average score in cm (VAS scale)  | 4.9 ± 2.1                   | 0.3 ± 0.8*             |

Note. * — p <0.05 when comparing two values within a group.

Table 4. Peripheral lymphocyte subpopulations in patients with VV (C6) who received treatment with and without Phlogenzym

| Parameter | Experimental group (n = 20) | Control group (n = 18) |
|-----------|-----------------------------|------------------------|
| CD19+     | 7.7 ± 0.79                  | 8.8 ± 0.9              |
| CD3+      | 73.1 ± 1.76                 | 74.6 ± 1.9             |
| CD3+CD4+  | 47.0 ± 2.2                  | 48.4 ± 2.2             |
| CD3+CD8+  | 24.7 ± 2.8                  | 23.9 ± 1.7             |
| CD3+CD25+ | 4.1 ± 0.3                   | 3.4 ± 0.3              |
| CD4+CD25+Bright | 3.2 ± 0.3 | 2.4 ± 0.2*             |
| CD4+CD45RA | 16.8 ± 2.0                 | 16.3 ± 2.1             |
| CD45RA+   | 57.4 ± 1.8                  | 54.0 ± 1.8*            |
| CD4+CD45RO+ | 26.7 ± 1.6             | 30.9 ± 1.5*            |
| CD45RO+   | 36.5 ± 1.9                  | 44.8 ± 2.2*            |
| CD4+CD45RA+/CD4+CD45RO+ | 0.7 ± 0.1 | 0.5 ± 0.1*             |
| CD45RA+/CD45RO+ | 1.6 ± 0.1               | 1.3 ± 0.1*             |

Note. The results are presented as M ± m. * — p <0.05 when comparing two values within a group.

DISCUSSION

The results of the lymphocyte subpopulation analysis and lymphocyte functional activity in patients with VV (C6) showed beneficial clinical effects of systemic enzyme therapy with

The analysis of CD45-T-lymphocytes revealed almost no changes in CD4+CD45RA+/CD4+CD45RO+ and CD45RA+/CD45RO+ ratios after treatment in the control group, while the experimental group demonstrated a significant decrease in these parameters (Table 4).
Phlogenzym, a statistically significant reduction in the number of regulatory CD4+CD25high T-cells and an increase in CD4+CD45RO+ memory cells.

The described lymphocyte subpopulations are associated with the inhibition of the synthesis of proinflammatory cytokines and the antigen-presenting function of dendritic cells and macrophages, cell apoptosis induction, decreased generation of type 1 and 2 T-helpers (Th1, Th2) and reduced cytokine production by the latter. This leads to a less effective immune response and contributes to the development of chronic inflammation [17]. An important advantage of memory T-cells that constantly circulate in all organs and tissues of the body even in the absence of any inflammation over naïve T-lymphocytes is their ability to detect antigens and eliminate them long before they reach secondary lymphoid structures [18].

After treatment completion, multidirectional dynamics of Treg and memory T-cells content in blood were revealed in the experimental group that corresponded with the observed positive clinical changes. This indicates a more effective immune response in patients who received Phlogenzym.

CONCLUSIONS

The present study demonstrated positive effects of systemic enzyme therapy on the regenerative processes in damaged tissues and on the function of T-cell mediated immunity in patients with CVI (C6). The results of this study validate the inclusion of immunomodulatory drugs into the treatment protocol. Immunomodulatory drugs contribute to the regression of clinical symptoms of CVI and accelerate the healing process of stage I-III VTU.

References

1. Lipinskitz EM, Lechenie troficheskih yazv nizhih konechnostey. Moscow: Meditsina; 2001: 160 p. Russian.
2. Saveliev VS, Kirienko AI, Bogachev VYu, Bogdanets LI. Chronic venous diseases in the Russian Federation. Results of VEIN CONSULT international research program]. Flebology. 2010. 4 (3): 9–12. Russian.
3. Bradbury AW. Epidemiology and aetiology of C4-6 disease. Phlebology. 2010 Oct; 25 Suppl 1: 2–8. DOI: 10.1258/ phleb.2010.010s01.
4. Khanevich MD, Khrupkin VI, Shchelkov AL, Fominykh OV. Oslozhnennye formy kholonektozov venoznoy nedostatochnosti nizhih konechnostey. Moscow: MedEkspertPress; Petrozavodsk: IntelTek; 2003. P. 53–8. Russian.
5. Kirienko AI. Fleboflebologicheskie problemy klinicheskoy praktiki. Moscow: MosMedVuzPress; 2003. 153–6. Russian.
6. Assotsiatsiya flebologov Rossii, Vserossiyskoe obshchestvo flebologov. Rossiniye meditsinskiye vesti. 2007; 12 (4): 53–8. Russian.
7. Khanevich MD, Khrupkin VI, Shchelkov AL, Fominykh OV. Phlebology. 2010. 4 (1): 9–12. Russian.
8. Lebedev KA, Ponyakina ID, Kozachenko NV. Physiology of chronic inflammatory processes and their treatment. Human Physiology. 2000; 160 (3): 75. Russian.
9. Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008 Jan; 47 (1): 183–92. DOI: 10.1016/j.jvs.2007.09.028.
10. Bergan JJ, Pascarella L, Schmid-Schönbein GW. Pathogenesis of primary chronic venous disease: Insights from animal models of venous hypertension. J Vasc Surg. 2008 Jan; 47 (1): 183–92. DOI: 10.1016/j.jvs.2007.09.028.
11. Кириенко А. И., Атауллаханов Р. И., Богачев В. Ю., Богданец Л. И., Пичугин В. Б. Трофические язвы венозной этиологии и их связь с иммунным статусом. Ангиология и сосудистая хирургия, 2007; 13 (1): 76–86.

12. Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman M, Michelson AD. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg. 1999 Nov; 30 (5): 844–51.

13. Štvrtinova V, Jahnova E, Weissova S, Horvathova M, Ferencik M. Expression of adhesion molecules on leukocytes of patients with chronic venous insufficiency. Phlebologie. 2002; 31 (3): 63–8.

14. Takase S, Bergan JJ, Schmid-Schönbein G. Expression of adhesion molecules and cytokines on saphenous veins in chronic venous insufficiency. Ann Vasc Surg. 2000 Sep; 14 (5): 427–35.

15. Кириенко А. И., Кошкин В. М., Богачев В. Ю. Системная энзимотерапия в ангиологии. В сб.: Материалы Всероссийской научно-практической конференции хирургов. Всероссийская научно-практическая конференция хирургов; Калуга, 26–27 сентября 1996 г. Калуга; 1996. С. 91.

16. Кириенко А. И., Кошкин В. М., Агафонов В. Ф. Системная энзимотерапия постстомботических болезней. В сб.: Критическая ишемия. Итоги XX века. Материалы 3-го Международного конгресса северных стран и регионов; Петрозаводск–Париж, 1999 г. Петрозаводск; 1999. С. 151.

17. Железникова Г. Ф. Регуляторные T-лимфоциты в иммунном ответе на инфекцию. Журнал инфектологии. 2011; 3 (1): 6–13.

18. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001 Mar 23; 291 (5512): 2413–7.